| Tom Swick

Attending the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego was more significant to me personally than the previous two I attended. Nine years after my diagnosis, I find myself in a relapse for the first time, after only one treatment regimen. With so many clinical trials leading to stringent […]

The Fireworks

| Tom Swick

Saturday night ended with a very successful IMF Media and Grant Awards Reception, at the Ultimate Skybox, with a 15th floor view of the Petco Park playing field on one side, and Seaport Village and the harbor on another. Robert A. Kyle, MD, presented the Brian D. Novis Research Grant Awards. I was happy to […]

The fire hose is open

| Tom Swick

Here I am at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego. This is my third time at ASH. Three different cities, but some things never change: big crowds, lots of walking, and drinking from a fire hose of information. I started with the IMF Satellite Symposium on Friday, […]

Forecast: clear, blue, and green

| Tom Swick

Growing up in Western Pennsylvania, Sunday afternoons in the fall usually meant watching a football doubleheader on TV. Often, the late game featured the Chargers, at home in San Diego. It never failed to strike me that the grass looked greener, the sky looked bluer, and even that the announcers sounded clearer. I moved to […]


Tom Swick

Tom Swick is chairman of the Orange County (CA) Multiple Myeloma Support Group. He was diagnosed with IgA-lambda type myeloma in 2007 at age 54, and feels very fortunate to have maintained a stable remission for nearly nine years, using Revlimid® in various dosages and combinations. This fall, he began searching for the treatment that will provide the next nine-year remission (or CURE!). Tom keeps fit and active doing group exercise classes. He worked as a software engineer in the computer and aerospace industries, and lives in San Clemente, CA, with his wife Judy. They have three daughters. Thrilled to attend ASH again, Tom is interested in the application of new drug combinations and in the treatment of relapsed myeloma.

Follow Tom on Twitter